{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:35:45Z","timestamp":1791329745316,"version":"4.3.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,1,23]],"date-time":"2015-01-23T00:00:00Z","timestamp":1421971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"},{"start":{"date-parts":[[2015,1,23]],"date-time":"2015-01-23T00:00:00Z","timestamp":1421971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"DOI":"10.1038\/emm.2014.102","type":"journal-article","created":{"date-parts":[[2015,1,23]],"date-time":"2015-01-23T07:55:29Z","timestamp":1421999729000},"page":"e136-e136","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Epstein Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic target"],"prefix":"10.1038","volume":"47","author":[{"given":"Eric","family":"Tse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yok-Lam","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,1,23]]},"reference":[{"key":"BFemm2014102_CR1","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/S0140-6736(64)91524-7","volume":"1","author":"MA Epstein","year":"1964","unstructured":"Epstein MA, Achong BG, Barr YM . Virus particles in cultured lymphoblasts from Burkitt\u2019s lymphoma. Lancet 1964; 1: 702\u2013703.","journal-title":"Lancet"},{"key":"BFemm2014102_CR2","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1056\/NEJM200008173430707","volume":"343","author":"JI Cohen","year":"2000","unstructured":"Cohen JI . Epstein-Barr virus infection. N Engl J Med 2000; 343: 481\u2013492.","journal-title":"N Engl J Med"},{"key":"BFemm2014102_CR3","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/nrclinonc.2012.111","volume":"9","author":"CM Bollard","year":"2012","unstructured":"Bollard CM, Rooney CM, Heslop HE . T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat Rev Clin Oncol 2012; 9: 510\u2013519.","journal-title":"Nat Rev Clin Oncol"},{"key":"BFemm2014102_CR4","doi-asserted-by":"publisher","first-page":"12250","DOI":"10.1073\/pnas.200366597","volume":"97","author":"GJ Babcock","year":"2000","unstructured":"Babcock GJ, Thorley-Lawson DA . Tonsillar memory B cells, latently infected with Epstein-Barr virus, express the restricted pattern of latent genes previously found only in Epstein-Barr virus-associated tumors. Proc Natl Acad Sci U S A. 2000; 97: 12250\u201312255.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"BFemm2014102_CR5","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1084\/jem.190.4.567","volume":"190","author":"GJ Babcock","year":"1999","unstructured":"Babcock GJ, Decker LL, Freeman RB, Thorley-Lawson DA . Epstein-barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. J Exp Med 1999; 190: 567\u2013576.","journal-title":"J Exp Med"},{"key":"BFemm2014102_CR6","first-page":"358","volume":"12","author":"N Neparidze","year":"2014","unstructured":"Neparidze N, Lacy J . Malignancies associated with epstein-barr virus: pathobiology, clinical features, and evolving treatments. Clin Adv Hematol Oncol 2014; 12: 358\u2013371.","journal-title":"Clin Adv Hematol Oncol"},{"key":"BFemm2014102_CR7","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.beha.2012.01.001","volume":"25","author":"LD Kaplan","year":"2012","unstructured":"Kaplan LD . HIV-associated lymphoma. Best Pract Res Clin Haematol 2012; 25: 101\u2013117.","journal-title":"Best Pract Res Clin Haematol"},{"key":"BFemm2014102_CR8","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/bmt.2013.96","volume":"49","author":"L Rasche","year":"2014","unstructured":"Rasche L, Kapp M, Einsele H, Mielke S . EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT. Bone Marrow Transplant 2014; 49: 163\u2013167.","journal-title":"Bone Marrow Transplant"},{"key":"BFemm2014102_CR9","doi-asserted-by":"publisher","first-page":"4992","DOI":"10.1182\/blood-2008-09-178046","volume":"113","author":"O Landgren","year":"2009","unstructured":"Landgren O, Gilbert ES, Rizzo JD, Soci\u00e9 G, Banks PM, Sobocinski KA et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 2009; 113: 4992\u20135001.","journal-title":"Blood"},{"key":"BFemm2014102_CR10","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/blood.V95.3.807.003k24_807_814","volume":"95","author":"A Gustafsson","year":"2000","unstructured":"Gustafsson A, Levitsky V, Zou JZ, Frisan T, Dalianis T, Ljungman P et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 2000; 95: 807\u2013814.","journal-title":"Blood"},{"key":"BFemm2014102_CR11","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1182\/blood.V97.5.1165","volume":"97","author":"SJ Stevens","year":"2001","unstructured":"Stevens SJ, Verschuuren EA, Pronk I, van Der Bij W, Harmsen MC, The TH et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 2001; 97: 1165\u20131171.","journal-title":"Blood"},{"key":"BFemm2014102_CR12","doi-asserted-by":"publisher","first-page":"4364","DOI":"10.1182\/blood.V99.12.4364","volume":"99","author":"JW van Esser","year":"2002","unstructured":"van Esser JW, Niesters HG, van der Holt B, Meijer E, Osterhaus AD, Gratama JW et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002; 99: 4364\u20134369.","journal-title":"Blood"},{"key":"BFemm2014102_CR13","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1182\/blood.V95.4.1502.004k40_1502_1505","volume":"95","author":"I Kuehnle","year":"2000","unstructured":"Kuehnle I, Huls MH, Liu Z, Semmelmann M, Krance RA, Brenner MK et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 2000; 95: 1502\u20131505.","journal-title":"Blood"},{"key":"BFemm2014102_CR14","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1056\/NEJM199404283301703","volume":"330","author":"EB Papadopoulos","year":"1994","unstructured":"Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994; 330: 1185\u20131191.","journal-title":"N Engl J Med"},{"key":"BFemm2014102_CR15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1089\/scd.1.1995.4.73","volume":"4","author":"CA Smith","year":"1995","unstructured":"Smith CA, Ng CY, Heslop HE, Holladay MS, Richardson S, Turner EV et al. Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. J Hematother 1995; 4: 73\u201379.","journal-title":"J Hematother"},{"key":"BFemm2014102_CR16","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1084\/jem.183.3.1215","volume":"183","author":"JF Lacerda","year":"1996","unstructured":"Lacerda JF, Ladanyi M, Louie DC, Fernandez JM, Papadopoulos EB, O'Reilly RJ . Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid\/scid mice. J Exp Med 1996; 183: 1215\u20131228.","journal-title":"J Exp Med"},{"key":"BFemm2014102_CR17","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nm0596-551","volume":"2","author":"HE Heslop","year":"1996","unstructured":"Heslop HE, Ng CY, Li C, Smith CA, Loftin SK, Krance RA et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996; 2: 551\u2013555.","journal-title":"Nat Med"},{"key":"BFemm2014102_CR18","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1182\/blood.V91.8.2925.2925_2925_2934","volume":"91","author":"MA Roskrow","year":"1998","unstructured":"Roskrow MA, Suzuki N, Gan Yj, Sixbey JW, Ng CY, Kimbrough S et al. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood 1998; 91: 2925\u20132934.","journal-title":"Blood"},{"key":"BFemm2014102_CR19","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1182\/blood.V92.5.1549.417k32_1549_1555","volume":"92","author":"CM Rooney","year":"1998","unstructured":"Rooney CM, Smith CA, Ng CY, Loftin SK, Sixbey JW, Gan Y et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998; 92: 1549\u20131555.","journal-title":"Blood"},{"key":"BFemm2014102_CR20","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","volume":"115","author":"HE Heslop","year":"2010","unstructured":"Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010; 115: 925\u2013935.","journal-title":"Blood"},{"key":"BFemm2014102_CR21","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1182\/blood-2011-08-371971","volume":"119","author":"E Doubrovina","year":"2012","unstructured":"Doubrovina E, Oflaz-Sozmen B, Prockop SE, Kernan NA, Abramson S, Teruya-Feldstein J et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood 2012; 119: 2644\u20132656.","journal-title":"Blood"},{"key":"BFemm2014102_CR22","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/j.1399-0012.2011.01593.x","volume":"26","author":"TS Chan","year":"2012","unstructured":"Chan TS, Hwang YY, Gill H, Au WY, Leung AY, Tse E et al. Post-transplant lymphoproliferative diseases in Asian solid organ transplant recipients: late onset and favorable response to treatment. Clin Transplant 2012; 26: 679\u2013683.","journal-title":"Clin Transplant"},{"key":"BFemm2014102_CR23","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1200\/JCO.2009.25.4961","volume":"28","author":"AM Evens","year":"2010","unstructured":"Evens AM, David KA, Helenowski I, Nelson B, Kaufman D, Kircher SM et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol 2010; 28: 1038\u20131046.","journal-title":"J Clin Oncol"},{"key":"BFemm2014102_CR24","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1097\/00007890-199706150-00027","volume":"63","author":"DJ Emanuel","year":"1997","unstructured":"Emanuel DJ, Lucas KG, Mallory GB Jr, Edwards-Brown MK, Pollok KE, Conrad PD et al. Treatment of posttransplant lymphoproliferative disease in the central nervous system of a lung transplant recipient using allogeneic leukocytes. Transplantation 1997; 63: 1691\u20131694.","journal-title":"Transplantation"},{"key":"BFemm2014102_CR25","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1097\/00007890-200110270-00012","volume":"72","author":"T Haque","year":"2001","unstructured":"Haque T, Taylor C, Wilkie GM, Murad P, Amlot PL, Beath S et al. Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells. Transplantation 2001; 72: 1399\u20131402.","journal-title":"Transplantation"},{"key":"BFemm2014102_CR26","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1182\/blood.V99.7.2592","volume":"99","author":"P Comoli","year":"2002","unstructured":"Comoli P, Labirio M, Basso S, Baldanti F, Grossi P, Furione M et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 2002; 99: 2592\u20132598.","journal-title":"Blood"},{"key":"BFemm2014102_CR27","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1182\/blood-2006-05-021782","volume":"108","author":"B Savoldo","year":"2006","unstructured":"Savoldo B, Goss JA, Hammer MM, Zhang L, Lopez T, Gee AP et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood 2006; 108: 2942\u20132949.","journal-title":"Blood"},{"key":"BFemm2014102_CR28","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1111\/j.1600-6143.2005.00854.x","volume":"5","author":"P Comoli","year":"2005","unstructured":"Comoli P, Maccario R, Locatelli F, Valente U, Basso S, Garaventa A et al. Treatment of EBV-related post-renal transplant lymphoproliferative disease with a tailored regimen including EBV-specific T cells. Am J Transplant 2005; 5: 1415\u20131422.","journal-title":"Am J Transplant"},{"key":"BFemm2014102_CR29","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/S0140-6736(02)09672-1","volume":"360","author":"T Haque","year":"2002","unstructured":"Haque T, Wilkie GM, Taylor C, Amlot PL, Murad P, Iley A et al. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 2002; 360: 436\u2013442.","journal-title":"Lancet"},{"key":"BFemm2014102_CR30","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1182\/blood-2006-12-063008","volume":"110","author":"T Haque","year":"2007","unstructured":"Haque T, Wilkie GM, Jones MM, Higgins CD, Urquhart G, Wingate P et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007; 110: 1123\u20131131.","journal-title":"Blood"},{"key":"BFemm2014102_CR31","doi-asserted-by":"publisher","first-page":"5045","DOI":"10.1182\/blood-2010-04-281873","volume":"116","author":"JN Barker","year":"2010","unstructured":"Barker JN, Doubrovina E, Sauter C, Jaroscak JJ, Perales MA, Doubrovin M et al. Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. Blood 2010; 116: 5045\u20135049.","journal-title":"Blood"},{"key":"BFemm2014102_CR32","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/bjh.13051","volume":"167","author":"MA Vickers","year":"2014","unstructured":"Vickers MA, Wilkie GM, Robinson N, Rivera N, Haque T, Crawford DH et al. Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease. Br J Haematol 2014; 167: 402\u2013410.","journal-title":"Br J Haematol"},{"key":"BFemm2014102_CR33","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1182\/blood.V89.6.1978","volume":"89","author":"AP Sing","year":"1997","unstructured":"Sing AP, Ambinder RF, Hong DJ, Jensen M, Batten W, Petersdorf E et al. Isolation of Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes that lyse Reed-Sternberg cells: implications for immune-mediated therapy of EBV+ Hodgkin's disease. Blood 1997; 89: 1978\u20131986.","journal-title":"Blood"},{"key":"BFemm2014102_CR34","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1084\/jem.20040890","volume":"200","author":"CM Bollard","year":"2004","unstructured":"Bollard CM, Aguilar L, Straathof KC, Gahn B, Huls MH, Rousseau A et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med 2004; 200: 1623\u20131633.","journal-title":"J Exp Med"},{"key":"BFemm2014102_CR35","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.1182\/blood-2002-01-0039","volume":"100","author":"B Savoldo","year":"2002","unstructured":"Savoldo B, Huls MH, Liu Z, Okamura T, Volk HD, Reinke P et al. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood 2002; 100: 4059\u20134066.","journal-title":"Blood"},{"key":"BFemm2014102_CR36","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","volume":"32","author":"CM Bollard","year":"2014","unstructured":"Bollard CM, Gottschalk S, Torrano V, Diouf O, Ku S, Hazrat Y et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol 2014; 32: 798\u2013808.","journal-title":"J Clin Oncol"},{"key":"BFemm2014102_CR37","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.semcancer.2014.01.003","volume":"26","author":"I Tempera","year":"2014","unstructured":"Tempera I, Lieberman PM . Epigenetic regulation of EBV persistence and oncogenesis. Semin Cancer Biol 2014; 26: 22\u201329.","journal-title":"Semin Cancer Biol"},{"key":"BFemm2014102_CR38","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1182\/blood.V90.11.4480","volume":"90","author":"KD Robertson","year":"1997","unstructured":"Robertson KD, Ambinder RF . Methylation of the Epstein-Barr virus genome in normal lymphocytes. Blood 1997; 90: 4480\u20134484.","journal-title":"Blood"},{"key":"BFemm2014102_CR39","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1182\/blood.V88.8.3129.bloodjournal8883129","volume":"88","author":"KD Robertson","year":"1996","unstructured":"Robertson KD, Manns A, Swinnen LJ, Zong JC, Gulley ML, Ambinder RF . CpG methylation of the major Epstein-Barr virus latency promoter in Burkitt's lymphoma and Hodgkin's disease. Blood 1996; 88: 3129\u20133136.","journal-title":"Blood"},{"key":"BFemm2014102_CR40","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.semcancer.2014.01.002","volume":"26","author":"SC Kenney","year":"2014","unstructured":"Kenney SC, Mertz JE . Regulation of the latent-lytic switch in Epstein-Barr virus. Semin Cancer Biol 2014; 26: 60\u201368.","journal-title":"Semin Cancer Biol"},{"key":"BFemm2014102_CR41","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1182\/blood-2011-06-362434","volume":"119","author":"SK Ghosh","year":"2012","unstructured":"Ghosh SK, Perrine SP, Williams RM, Faller DV . Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents. Blood 2012; 119: 1008\u20131017.","journal-title":"Blood"},{"key":"BFemm2014102_CR42","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1182\/blood-2006-01-024703","volume":"109","author":"SP Perrine","year":"2007","unstructured":"Perrine SP, Hermine O, Small T, Suarez F, O'Reilly R, Boulad F et al. A phase 1\/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood 2007; 109: 2571\u20132578.","journal-title":"Blood"},{"key":"BFemm2014102_CR43","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1158\/1078-0432.CCR-09-2424","volume":"16","author":"W Tang","year":"2010","unstructured":"Tang W, Harmon P, Gulley ML, Mwansambo C, Kazembe PN, Martinson F et al. Viral response to chemotherapy in endemic burkitt lymphoma. Clin Cancer Res 2010; 16: 2055\u20132064.","journal-title":"Clin Cancer Res"},{"key":"BFemm2014102_CR44","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.clml.2012.11.003","volume":"13","author":"D Olson","year":"2013","unstructured":"Olson D, Gulley ML, Tang W, Wokocha C, Mechanic O, Hosseinipour M et al. Phase I clinical trial of valacyclovir and standard of care cyclophosphamide in children with endemic Burkitt lymphoma in Malawi. Clin Lymphoma Myeloma Leuk 2013; 13: 112\u2013118.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"BFemm2014102_CR45","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1097\/00007890-199709270-00010","volume":"64","author":"IA Darenkov","year":"1997","unstructured":"Darenkov IA, Marcarelli MA, Basadonna GP, Friedman AL, Lorber KM, Howe JG et al. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation 1997; 64: 848\u2013852.","journal-title":"Transplantation"},{"key":"BFemm2014102_CR46","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S1053-2498(01)00407-7","volume":"21","author":"MA Malouf","year":"2002","unstructured":"Malouf MA, Chhajed PN, Hopkins P, Plit M, Turner J, Glanville AR . Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients. J Heart Lung Transplant 2002; 21: 547\u2013554.","journal-title":"J Heart Lung Transplant"},{"key":"BFemm2014102_CR47","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1111\/j.1600-6143.2005.01115.x","volume":"5","author":"DP Funch","year":"2005","unstructured":"Funch DP, Walker AM, Schneider G, Ziyadeh NJ, Pescovitz MD . Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 2005; 5: 2894\u20132900.","journal-title":"Am J Transplant"},{"key":"BFemm2014102_CR48","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1002\/lt.21498","volume":"14","author":"L Hierro","year":"2008","unstructured":"Hierro L, D\u00edez-Dorado R, D\u00edaz C, De la Vega A, Frauca E, Camarena C et al. Efficacy and safety of valganciclovir in liver-transplanted children infected with Epstein-Barr virus. Liver Transpl 2008; 14: 1185\u20131193.","journal-title":"Liver Transpl"},{"key":"BFemm2014102_CR49","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jcv.2014.01.005","volume":"59","author":"H Gill","year":"2014","unstructured":"Gill H, Hwang YY, Chan TS, Pang AW, Leung AY, Tse E et al. Valganciclovir suppressed Epstein Barr virus reactivation during immunosuppression with alemtuzumab. J Clin Virol 2014; 59: 255\u2013258.","journal-title":"J Clin Virol"},{"key":"BFemm2014102_CR50","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1040-8428(00)00046-9","volume":"34","author":"JL Hsu","year":"2000","unstructured":"Hsu JL, Glaser SL . Epstein-barr virus-associated malignancies: epidemiologic patterns and etiologic implications. Crit Rev Oncol Hematol 2000; 34: 27\u201353.","journal-title":"Crit Rev Oncol Hematol"},{"key":"BFemm2014102_CR51","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1040-8428(02)00115-4","volume":"44","author":"H Kanegane","year":"2002","unstructured":"Kanegane H, Nomura K, Miyawaki T, Tosato G . Biological aspects of Epstein-Barr virus (EBV)-infected lymphocytes in chronic active EBV infection and associated malignancies. Crit Rev Oncol Hematol 2002; 44: 239\u2013249.","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Experimental & Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/emm2014102.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/emm2014102","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/emm2014102.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T09:35:27Z","timestamp":1672911327000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/emm2014102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,23]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,1]]}},"alternative-id":["BFemm2014102"],"URL":"https:\/\/doi.org\/10.1038\/emm.2014.102","relation":{},"ISSN":["2092-6413"],"issn-type":[{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,23]]},"assertion":[{"value":"29 September 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}